North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.
Feature|Articles|June 12, 2026
5 FAQs: Ebola Outbreaks and the Challenge of Public Trust
Author(s)Sabrina McCrear
Fact checked by: Laura Joszt, MA, Amy Bucher, PhD
Distrust, misinformation, and conflict complicate Ebola response efforts in the DRC, highlighting broader challenges to public health trust.
Advertisement
Advertisement
The 17th
Related to this article
Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
NCCN concordance won't ensure coverage; OAB risk tied to income; 91% offer bispecifics; ruxolitinib spend hits $49.6M; TALK SAFE Act aids telepsychiatry.
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.
A new type of eye drug matched standard anti-VEGF therapy in a large trial for diabetic macular edema, a disease affecting 1.6 million Americans.
Advertisement
Advertisement